General American Investors Co. Inc. Acquires New Holdings in InMode Ltd. (NASDAQ:INMD)

General American Investors Co. Inc. purchased a new position in shares of InMode Ltd. (NASDAQ:INMD - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 67,784 shares of the healthcare company's stock, valued at approximately $1,202,000. General American Investors Co. Inc. owned approximately 0.10% of InMode at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. CWM LLC increased its stake in InMode by 106.4% in the first quarter. CWM LLC now owns 2,369 shares of the healthcare company's stock valued at $42,000 after purchasing an additional 1,221 shares during the period. GAMMA Investing LLC boosted its holdings in shares of InMode by 13,923.8% in the first quarter. GAMMA Investing LLC now owns 2,945 shares of the healthcare company's stock valued at $520,000 after acquiring an additional 2,924 shares in the last quarter. Orion Capital Management LLC purchased a new stake in shares of InMode in the fourth quarter valued at about $65,000. Farther Finance Advisors LLC boosted its holdings in shares of InMode by 26.2% in the fourth quarter. Farther Finance Advisors LLC now owns 5,555 shares of the healthcare company's stock valued at $93,000 after acquiring an additional 1,154 shares in the last quarter. Finally, Covestor Ltd boosted its holdings in shares of InMode by 13.9% in the fourth quarter. Covestor Ltd now owns 5,936 shares of the healthcare company's stock valued at $99,000 after acquiring an additional 723 shares in the last quarter. 68.04% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have recently weighed in on INMD shares. Needham & Company LLC reaffirmed a "hold" rating on shares of InMode in a report on Monday, April 28th. Barclays lowered their target price on shares of InMode from $29.00 to $24.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 30th. Jefferies Financial Group lowered their target price on shares of InMode from $16.00 to $15.00 and set a "hold" rating on the stock in a research report on Monday, April 14th. Baird R W lowered shares of InMode from a "strong-buy" rating to a "hold" rating in a research report on Monday, April 28th. Finally, UBS Group lowered their target price on shares of InMode from $19.00 to $16.25 and set a "neutral" rating on the stock in a research report on Tuesday, April 29th. Seven research analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $18.54.

InMode Price Performance

INMD stock traded down $0.20 on Friday, hitting $13.90. 1,246,840 shares of the company were exchanged, compared to its average volume of 1,202,394. InMode Ltd. has a twelve month low of $13.14 and a twelve month high of $19.85. The business's fifty day moving average is $14.39 and its two-hundred day moving average is $16.12. The stock has a market capitalization of $878.62 million, a price-to-earnings ratio of 5.97 and a beta of 1.95.

InMode (NASDAQ:INMD - Get Free Report) last released its quarterly earnings data on Monday, April 28th. The healthcare company reported $0.31 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.45 by ($0.14). InMode had a return on equity of 17.17% and a net margin of 44.79%. The business had revenue of $77.87 million during the quarter, compared to analyst estimates of $82.21 million. During the same period in the previous year, the company earned $0.32 EPS. InMode's revenue was down 3.0% on a year-over-year basis. Equities research analysts expect that InMode Ltd. will post 1.75 earnings per share for the current year.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.